Quarterly Report • Apr 24, 2025
Quarterly Report
Open in ViewerOpens in native device viewer



2.1% 13.5%
Organic sales growth EBITA margin excl. IAC
| 2025:1 | 2024:1 | % | |
|---|---|---|---|
| Net sales, SEKm | 34,976 | 34,850 | 0 |
| Organic sales growth, % | 2.1 | -4.0 | |
| EBITA, SEKm | 4,718 | 4,523 | 4 |
| EBITA margin, % | 13.5 | 13.0 | |
| EBITA excl. IAC, SEKm | 4,706 | 4,880 | -4 |
| EBITA margin excl. IAC, % | 13.5 | 14.0 | |
| Profit for the period, SEKm | 3,083 | 2,477 | 24 |
| Earnings per share, SEK | 4.43 | 3.51 | 26 |
| Earnings per share*, SEK | 4.65 | 4.33 | 7 |
| ROCE, % | 16.7 | 15.9 | |
| ROCE excl. IAC, % | 16.7 | 17.2 | |
| Operating cash flow, SEKm | 3,765 | 4,253 | -11 |
* Earnings per share excl. IAC and amortization of acquisition-related intangible assets
| 2025:1 | 2024:1 | % | |
|---|---|---|---|
| Profit for the period, SEKm | 3,083 | 11,493 | -73 |
| Earnings per share, SEK | 4.43 | 16.21 | -73 |
| Net debt/EBITDA excl. IAC | 1.02 | 1.34 |

Essity began the year with positive organic sales growth in all business areas, stable profitability and continued strong cash flow. In these turbulent times, Essity's strength becomes clear – with production close to our customers and consumers, we deliver leading hygiene and health solutions that are needed every day.
All business areas reported positive organic sales growth for the first quarter of 2025 compared to the same period in 2024. Growth was primarily driven by higher prices. In Health & Medical and Consumer Goods, volumes were higher, while volumes were lower in Professional Hygiene, mainly due to lower demand in North America.
During the quarter, we achieved product superiority of above 70%, meaning that customers and consumers rate Essity's products as the best in the market for more than 70% of the company's offerings. This is the highest percentage to date and the increase is the result of our latest product launches.
Earnings (EBITA excl. IAC) were slightly lower, mainly due to the higher cost of goods sold while higher sales prices increased earnings. EBITA margin excl. IAC was lower compared with the first quarter of 2024 but higher compared with the fourth quarter. Cash flow
continued to develop strongly, mainly due to the robust earnings, and the company's financial position is good.
The share buyback program that began in June 2024 was completed during the quarter, resulting in approximately 10 million shares being repurchased for SEK 3bn. The Annual General Meeting in March 2025 resolved to cancel own shares, which also took place after the end of the first quarter. The aim is to continue buying back shares as a recurring part of Essity's capital allocation, and on April 23 the Board of Directors resolved on a new SEK 3bn program, beginning on April 24, 2025.
Essity has sales in approximately 150 countries, but we expect that the changed trade tariffs will only have a limited impact on the company. Our production is close to our customers and consumers, with approximately 70 production facilities worldwide. For the parts of our operations that are nonetheless affected, we are reviewing our flows and actively striving to optimize our production and supply chain.
We remain committed to our ambition to accelerate the company's profitable growth during the year. We will achieve this through value-creating innovation, strong brands, efficiency improvements and by continuing our successful sustainability work.
President and CEO
Net sales increased 0.4% in the first quarter of 2025 compared with the corresponding period a year ago and amounted to SEK 34,976m (34,850).
Organic sales growth increased by 2.1%. All business areas reported positive organic growth. Volumes were higher in Health & Medical and Consumer Goods. However, volumes were lower in Professional Hygiene, mainly due to lower demand in North America. Higher prices in all business areas had a positive impact on growth. The product mix was also favorable with increased sales of premium products in Professional Hygiene.
Growth was good in Europe, with positive growth in all business areas. Growth was also positive in Latin America, with high growth in Consumer Goods and Professional Hygiene. Growth was negative in North America.
| % | 2025:1 vs 2024:1 |
|---|---|
| Total | 0.4 |
| Volume | 0.0 |
| Price/Mix | 2.1 |
| Organic growth | 2.1 |
| Acquisitions | 0.0 |
| Divestments | 0.0 |
| Currency translation | -1.7 |
The gross margin increased 0.7 percentage points to 32.8% (32.1). The gross margin excl. IAC decreased 0.4 percentage points to 32.8% (33.2). The cost of goods sold increased, mainly due to higher raw material and distribution costs. Energy costs were slightly lower. Cost savings amounted to approximately SEK 82m. Earnings were positively impacted by higher sales prices and a positive mix.
EBITA increased 4% to SEK 4,718m (4,523) and EBITA excl. IAC decreased 4% to SEK 4,706m (4,880). Excluding currency translation effects, EBITA excl. IAC decreased by 2%. The EBITA margin excl. IAC declined to 13.5% (14.0). Sales, general and administration costs increased to 19.4% (19.2), of which marketing costs accounted for 5.2% (5.5).
IAC amounted to SEK 32m (-426) mainly attributable to restructuring.
| SEKm | |
|---|---|
| EBITA excl. IAC 2024:1 | 4,880 |
| Volume | 39 |
| Price/Mix | 704 |
| Cost of goods sold | -610 |
| Sales & Admin | -166 |
| Currency translation | -98 |
| Other | -43 |
| EBITA excl. IAC 2025:1 | 4,706 |



Net sales Organic sales growth %


Financial items decreased to SEK -373m (-607) mainly on account of lower average net debt.
The tax expense was SEK 1,025m (1,050), corresponding to a tax rate of 25.0% (29.8). The tax expense excl. IAC was SEK 1,016m (1,144), corresponding to a tax rate of 24.9% (28.9).
Profit for the period, total operations, amounted to SEK 3,083m (11,493). Profit for the period, continuing operations, was SEK 3,083m (2,477).
Operating cash flow amounted to SEK 3,765m (4,253). Net cash flow for continuing operations was SEK 1,394m (21,081), and for total operations SEK 1,394m (20,614). During the quarter, Essity bought back 2,672,500 own Class B shares for a total amount of SEK 776m.
| SEKm | 2025:1 | 2024:1 |
|---|---|---|
| Operating cash surplus | 6,376 | 6,594 |
| Change in inventories | -868 | -557 |
| Change in operating receivables | 301 | -306 |
| Change in operating liabilities | -465 | 572 |
| Investments in non-current assets, net | -1,133 | -1,409 |
| Restructuring costs, etc. | -280 | -601 |
| Investments in operating assets through leases | -166 | -40 |
| Operating cash flow | 3,765 | 4,253 |
| Financial items | -373 | -607 |
| Income taxes paid | -1,222 | -1,013 |
| Other | 0 | 1 |
| Cash flow from current operations | 2,170 | 2,634 |
| Acquisitions of Group companies and other operations | ─ | -17 |
| Divestments of Group companies and other operations | ─ | 23,908 |
| Cash flow before transactions with shareholders | 2,170 | 26,525 |
| Dividend | ─1) | -5,443 |
| Dividend to non-controlling interests | ─ | -1 |
| Repurchase of own shares | -776 | ─ |
| Net cash flow, continuing operations | 1,394 | 21,081 |
| Net cash flow, discontinued operations | ─ | -467 |
| Net cash flow, total operations | 1,394 | 20,614 |
1)Dividend of SEK 5,711m resolved by the Annual General Meeting on March 27, 2025. Payment April 3, 2025.

Net debt decreased by SEK 3,995m compared with December 31, 2024 and amounted to SEK 26,774m. The Group's interest-bearing gross debt amounted to SEK 36,407m (42,749) at the end of the quarter. The average maturity period was 3.9 (3.8) years.
Compared with December 31, 2024, working capital decreased to SEK 5,211m, mainly due to an approved but not paid dividend. Working capital amounted to 4% (7) of net sales.
Equity attributable to owners of the Parent company decreased SEK 9,021m compared with December 31, 2024. Profit for the period attributable to owners of the Parent company increased the equity of owners of the Parent company by SEK 3,069m. Net translation effects reduced equity by SEK 6,138m. The dividend of SEK 5,711m and the buyback of own shares of SEK 776m reduced equity attributable to owners of the Parent company. The Group's total equity decreased SEK 9,037m during the quarter.
The SEK 3bn share buyback program, which began on June 17, 2024, was completed on March 13, 2025, when Essity had repurchased a total of 10,070,500 Class B own shares for SEK 3bn. As of March 31, 2025, Essity's holdings of own shares corresponded to 1.4% of the total number of shares outstanding. The Annual General Meeting on March 27, 2025 resolved to cancel own shares. After the end of the quarter, Essity therefore canceled 9,288,000 Class B own shares.

| 2503 | 2403 | 2412 |
|---|---|---|
| 5,211 | 9,609 | 10,746 |
| 106,478 | 116,439 | 119,510 |
| 26,774 | 34,263 | 30,769 |
| 0.34 | 0.42 | 0.35 |
| 67 | 50 | 59 |
| 1.04 | 1.46 | 1.19 |
| 1.02 | 1.34 | 1.16 |
| SEKm | 2503 | 2403 | 2412 |
|---|---|---|---|
| Net debt at the beginning of the period |
-30,769 | -53,703 | -53,703 |
| Net cash flow | 1,394 | 20,614 | 25,168 |
| Remeasurements to equity | 1,147 | 921 | 96 |
| Investments in non-operating assets through leases |
-319 | -211 | -581 |
| Translation differences | 1,773 | -1,884 | -1,749 |
| Net debt at the end of the period | -26,774 | -34,263 | -30,769 |

| % | 2025:1 | 2024:1 |
|---|---|---|
| ROCE | 16.7 | 15.9 |
| ROCE excl. IAC | 16.7 | 17.2 |
| ROE | 14.6 | 56.9 |
| ROE excl. IAC | 14.5 | 15.0 |
Net sales increased organically by 1.7%. Volumes were higher and prices developed positively. The product mix was stable.
Growth was good in both Europe and North America.
In Incontinence Products Health Care, volumes were slightly higher while sales prices and the product mix were marginally negative.
Organic growth in Medical Solutions was mainly driven by higher volumes combined with increased sales prices. The product mix was stable. Growth was good in all three therapeutic areas (wound care, compression therapy and orthopedics).
EBITA and the EBITA margin excl. IAC decreased. The cost of goods sold was higher, mainly driven by increased raw material costs. Higher volumes and sales prices had a positive impact on earnings, while investments in sales to drive growth increased costs. Currency translation effects had a negative impact on earnings of SEK 3m compared with the corresponding period a year ago.

During the quarter, an upgrade of TENA ProSkin all-in-one was launched within Incontinence Products Health Care. The product is uniquely designed to provide disabled persons increased comfort, dryness and leakage security. New ComfiStretch™ and DuoLock™ technologies provide a better fit and keep liquid away from the skin.
| % | 2025:1 vs 2024:1 |
|---|---|
| Total | 1.4 |
| Volume | 1.3 |
| Price/Mix | 0.4 |
| Organic growth | 1.7 |
| Acquisitions | 0.0 |
| Divestments | 0.0 |
| Currency translation | -0.3 |
| 2025:1 vs | % of net | ||
|---|---|---|---|
| % | 2024:1 | sales | |
| Incontinence Products Health Care | -0.1 | 58 | |
| Medical Solutions | 4.2 | 42 |
| 2025:1 | 2024:1 | % | |
|---|---|---|---|
| Net sales, SEKm | 6,936 | 6,842 | 1 |
| Organic sales growth, % | 1.7 | 2.6 | |
| Gross profit margin excl. IAC, % | 44.4 | 45.2 | |
| EBITA excl. IAC, SEKm | 1,231 | 1,290 | -5 |
| EBITA margin excl. IAC, % | 17.7 | 18.9 | |
| ROCE excl. IAC, % | 14.7 | 15.4 | |
| Operating cash flow, SEKm | 1,232 | 1,330 | -7 |

Europe North America Latin America Other


Net sales increased organically 2.9%, driven by higher volumes and sales prices.
Growth was good in Europe and high in Latin America.
Incontinence Products Retail and Feminine Care reported high organic growth, primarily driven by strong volume growth and also higher sales prices. In Baby Care, volumes were lower and the mix was negatively affected by an increased share of retailer brands. Growth in Consumer Tissue was mainly due to higher sales prices.
EBITA and the EBITA margin excl. IAC declined, mainly due to the higher cost of goods sold. The cost increase was mainly attributable to higher raw material costs in Consumer Tissue. Higher volumes and sales prices, cost savings and lower energy costs contributed positively to earnings. Sales costs were slightly higher. Currency translation effects had a negative impact on earnings of SEK 106m compared with the corresponding period a year ago.

The TENA MEN Protective Boxer features a new design that provides a more comfortable and discreet fit. The product has built-in protection with SpeedDry Zone textile technology for fast absorption.
| % | 2025:1 vs 2024:1 |
|---|---|
| Total | -0.3 |
| Volume | 1.2 |
| Price/Mix | 1.7 |
| Organic growth | 2.9 |
| Acquisitions | 0.0 |
| Divestments | 0.0 |
| Currency translation | -3.2 |
| % | 2025:1 vs 2024:1 |
% of net sales |
|---|---|---|
| Incontinence Products Retail | 6.9 | 15 |
| Feminine Care | 5.1 | 17 |
| Baby Care | -6.5 | 8 |
| Consumer Tissue | 2.7 | 59 |
| 2025:1 | 2024:1 | % | |
|---|---|---|---|
| Net sales, SEKm | 19,285 | 19,338 | 0 |
| Organic sales growth, % | 2.9 | -4.8 | |
| Gross profit margin excl. IAC, % | 29.5 | 30.4 | |
| EBITA excl. IAC, SEKm | 2,443 | 2,545 | -4 |
| EBITA margin excl. IAC, % | 12.7 | 13.2 | |
| ROCE excl. IAC, % | 18.2 | 19.1 | |
| Operating cash flow, SEKm | 1,657 | 2,331 | -29 |

Europe Latin America North America Other


Net sales increased organically by 0.7%, primarily driven by higher sales prices. The product mix also remained favorable with an increased share of premium products. Volumes were lower, negatively affected by lower demand in North America.
Growth was good in Europe and high in Latin America.
EBITA and the EBITA margin excl. IAC increased. Higher sales prices combined with the favorable mix trend and lower costs for energy had a positive impact on earnings. However, the total cost of goods sold was higher, mainly due to higher raw material costs. Lower volumes had a negative earnings effect. Sales costs were higher in order to drive growth. Currency translation effects had a positive impact on earnings of SEK 4m compared with the corresponding period a year ago.

Tork's strategic system comprising paper hand towels, soap and dispensers differentiates our offering from competitors. They are patented and offer substantial added value to our customers. They often reduce consumption, which is a benefit both from a cost and sustainability perspective.
| % | 2025:1 vs 2024:1 |
|---|---|
| Total | 0.8 |
| Volume | -3.6 |
| Price/Mix | 4.3 |
| Organic growth | 0.7 |
| Acquisitions | 0.0 |
| Divestments | 0.0 |
| Currency translation | 0.1 |
| 2025:1 | 2024:1 | % | |
|---|---|---|---|
| Net sales, SEKm | 8,757 | 8,686 | 1 |
| Organic sales growth, % | 0.7 | -6.9 | |
| Gross profit margin excl. IAC, % | 31.0 | 29.9 | |
| EBITA excl. IAC, SEKm | 1,413 | 1,332 | 6 |
| EBITA margin excl. IAC, % | 16.1 | 15.3 | |
| ROCE excl. IAC, % | 22.0 | 21.4 | |
| Operating cash flow, SEKm | 1,054 | 780 | 35 |
| 45% | 41% | 9% 5% | ||
|---|---|---|---|---|
| Europe | North America | Latin America | Other |


Sustainability is integrated into Essity's strategy and is a priority, with ambitious Group targets in several areas. The outcome for three of the targets is presented below. More information on these and other targets can be found in Essity's Annual Report.
| 2021 | 2022 | 2023 | 2024 | Q1 2025 |
|---|---|---|---|---|
| -45% | -39% | -58% | -66% | -58% |
Total recordable incidents (TRI) include lost time accidents (LTA), restricted work cases (RWC) and medical treatment cases (MTC)
Science-based emissions targets: 2030 Target: -35 % vs 2016
Reduction in absolute greenhouse gas emissions, Scope 1 and 2
| 2021 | 2022 | 2023 | 2024 | Q1 2025* |
|---|---|---|---|---|
| -16% | -17% | -27% | -27% | -27% |
*Outcome for last 12 months
Percentage leading to social and/or environmental improvements
| 2021 | 2022 | 2023 | 2024 | Q1 2025 |
|---|---|---|---|---|
| 59% | 68% | 85% | 87% | 84% |
On January 22, 2025, Essity announced that Magnus Groth is to step down as CEO for Essity during 2025. Magnus Groth has a notice period of one year. He will continue as President and CEO of Essity until a successor is appointed.
Essity's Annual General Meeting was held on March 27, 2025. The Meeting approved the Parent company income statement and balance sheet and the consolidated income statement and consolidated balance sheet for 2024. The meeting resolved on a dividend for the financial year 2024 of SEK 8.25 per share. Board members Maria Carell, Annemarie Gardshol, Magnus Groth, Jan Gurander, Torbjörn Lööf, Bert Nordberg, Barbara M. Thoralfsson and Karl Åberg were re-elected. Alexander Lacik and Katarina Martinson were elected as new directors. Ewa Björling had declined re-election. Jan Gurander was elected as the Chairman of the Board. The meeting resolved to amend the articles of association, to reduce the share capital through cancellation of own shares and to increase the share capital through a bonus issue. The Annual General Meeting authorized the Board of Directors to decide on buyback of Essity Class B shares and to transfer shares bought back by the company. These authorizations are valid until the next Annual General Meeting.
During the quarter, Essity received several awards for its sustainability activities. The company has been awarded a place on the Dow Jones Sustainability Index (DJSI), one of the world's most prestigious sustainability indices, and included on the global non-profit environmental organization CDP's "A List".
On April 24, 2025, Essity announced that the company's Board of Directors has resolved to utilize the authorization granted by the Annual General Meeting on March 27, 2025, and initiate a new program to buy back Class B shares in Essity for SEK 3bn. The program begins on April 24, 2025 and extends until the 2026 Annual General Meeting at the latest. The share repurchase will be financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share buyback program will be managed by BofA Securities Europe SA, which will decide on the date for repurchasing independently from and outside of Essity's influence. Repurchasing will take place on Nasdaq Stockholm in accordance with the stock exchange's issuer regulations and be implemented in accordance with the EU Market Abuse Regulation (MAR) and the European Commission's Delegated Regulation 2016/1052 (Safe Harbour Regulation).
Stockholm, April 24, 2025 Essity Aktiebolag (publ)
Magnus Groth President and CEO
This report has not been reviewed by the company's auditors.
NB: This information is such information that Essity Aktiebolag (publ) is obligated to make public pursuant to the EU Market Abuse Regulation. This report has been prepared in both Swedish and English versions. In case of variations in the content between the two versions, the Swedish version shall govern. The information was submitted for publication, through the agency of Karl Stoltz, Public Relations Director, at 07:00 CET on April 24, 2025.
| SEKm | 2025:1 | 2024:1 | % |
|---|---|---|---|
| Net sales | 34,976 | 34,850 | 0 |
| Cost of goods sold | -23,502 | -23,283 | |
| Items affecting comparability (IAC) - cost of goods sold | -10 | -366 | |
| Gross profit | 11,464 | 11,201 | 2 |
| Gross profit excl. IAC | 11,474 | 11,567 | -1 |
| Sales, general and administration | -6,768 | -6,689 | |
| Items affecting comparability (IAC) - sales, general and administration | 22 | 9 | |
| Share of results of associates and joint ventures1) | ─ | 2 | |
| Operating profit before amortization of acquisition-related intangible assets (EBITA) |
4,718 | 4,523 | 4 |
| Operating profit before amortization of acquisition-related intangible assets (EBITA) excl. IAC |
4,706 | 4,880 | -4 |
| Amortization of acquisition-related intangible assets | -256 | -320 | |
| Items affecting comparability (IAC) - acquisition-related intangible assets | 20 | -69 | |
| Operating profit | 4,482 | 4,134 | 8 |
| Operating profit excl. IAC | 4,450 | 4,560 | -2 |
| Share of results of associates and joint ventures1) | -1 | ─ | |
| Financial items | -373 | -607 | |
| Profit before tax | 4,108 | 3,527 | 16 |
| Profit before tax excl. IAC | 4,076 | 3,953 | 3 |
| Income taxes | -1,025 | -1,050 | |
| Profit for the period, continuing operations | 3,083 | 2,477 | 24 |
| Profit for the period excl. IAC, continuing operations | 3,060 | 2,809 | 9 |
| Profit for the period, discontinued operations | ─ | 9,016 | NA |
| Profit for the period, total operations | 3,083 | 11,493 | -73 |
| Items affecting comparability (IAC) before tax | 32 | -426 | |
| Items affecting comparability (IAC) after tax | 23 | -332 |
1) Until 2024, the share of results of associates and joint ventures was recognized in operating profit. From 2025 onwards, these results will be recognized below operating profit.
| SEKm | 2025:1 | 2024:1 |
|---|---|---|
| Earnings attributable to: | ||
| Owners of the Parent company | ||
| Profit for the period, continuing operations | 3,069 | 2,463 |
| Profit for the period, discontinued operations | ─ | 8,920 |
| Profit for the period, total operations | 3,069 | 11,383 |
| Non-controlling interests | ||
| Profit for the period, continuing operations | 14 | 14 |
| Profit for the period, discontinued operations | ─ | 96 |
| Profit for the period, total operations | 14 | 110 |
| Earnings per share - owners of the Parent company | ||
| Earnings per share before and after dilution effects, continuing operations, SEK |
4.43 | 3.51 |
| Earnings per share before and after dilution effects, discontinued operations, SEK |
─ | 12.70 |
| Earnings per share before and after dilution effects, total operations, SEK |
4.43 | 16.21 |
| Average numbers of shares before and after dilution effects, million | 693.4 | 702.3 |
| SEKm | 2025:1 | 2024:1 | % |
|---|---|---|---|
| Profit for the period, continuing operations | 3,083 | 2,477 | 24 |
| Profit for the period, discontinued operations | ─ | 9,016 | NA |
| Profit for the period, total operations | 3,083 | 11,493 | -73 |
| Other comprehensive income for the period | |||
| Items that will not be reclassified to the income statement | |||
| Actuarial gains/losses on defined benefit pension plans | 1,148 | 921 | |
| Fair value through other comprehensive income | -1 | 1 | |
| Income tax attributable to components in other comprehensive income | -284 | -237 | |
| Total, continuing operations | 863 | 685 | |
| Total operations | 863 | 685 |
| SEKm | 2025:1 | 2024:1 |
|---|---|---|
| Items that have been or may be reclassified subsequently to the income | ||
| statement Cash flow hedges: |
||
| Result from remeasurement of derivatives recognized in equity | -160 | -417 |
| Transferred to profit or loss for the period | -16 | 592 |
| Translation differences in foreign operations | -7,080 | 5,935 |
| Gains/losses from hedges of net investments in foreign operations | 942 | -1,041 |
| Income tax attributable to components in other comprehensive income | -175 | 165 |
| Total, continuing operations | -6,489 | 5,234 |
| Total, discontinued operations | ─ | -557 |
| Total operations | -6,489 | 4,677 |
| Other comprehensive income for the period, net of tax | -5,626 | 5,362 |
| Of which, continuing operations | 5,626 | 5,919 |
| Of which, discontinued operations | ─ | -557 |
| Total comprehensive income for the period | -2,543 | 16,855 |
| Of which, continuing operations | -2,543 | 8,396 |
| Of which, discontinued operations | ─ | 8,459 |
| Total comprehensive income attributable to: | ||
| Owners of the Parent company | -2,527 | 16,330 |
| Non-controlling interests | -16 | 525 |
| SEKm | Mar 31, 2025 | Mar 31, 2024 | Dec 31, 2024 |
|---|---|---|---|
| ASSETS | |||
| Non-current assets | |||
| Goodwill | 38,124 | 41,271 | 41,137 |
| Intangible assets | 19,343 | 21,968 | 20,734 |
| Property, plant and equipment | 45,097 | 47,328 | 48,304 |
| Right-of-use assets | 4,055 | 4,066 | 4,088 |
| Investments in associates and joint ventures | 330 | 309 | 351 |
| Shares and participations | 8 | 6 | 8 |
| Surplus in funded pension plans | 2,593 | 4,012 | 2,475 |
| Non-current financial assets | 221 | 123 | 128 |
| Deferred tax assets | 2,203 | 2,561 | 2,326 |
| Other non-current assets | 728 | 778 | 824 |
| Total non-current assets | 112,702 | 122,422 | 120,375 |
| Current assets | |||
| Inventories | 18,493 | 19,031 | 18,914 |
| Trade receivables | 22,278 | 23,686 | 23,538 |
| Current tax assets | 1,446 | 1,294 | 1,673 |
| Other current receivables | 3,586 | 3,267 | 4,480 |
| Current financial assets | 2,893 | 5,003 | 5,342 |
| Non-current assets held for sale | 76 | ─ | ─ |
| Cash and cash equivalents | 9,767 | 11,373 | 10,962 |
| Total current assets | 58,539 | 63,654 | 64,909 |
| Total assets | 171,241 | 186,076 | 185,284 |
| SEKm | Mar 31, 2025 | Mar 31, 2024 | Dec 31, 2024 |
|---|---|---|---|
| EQUITY AND LIABILITIES | |||
| Equity | |||
| Owners of the Parent company | |||
| Share capital | 2,350 | 2,350 | 2,350 |
| Reserves | 6,768 | 13,685 | 13,224 |
| Retained earnings including profit/loss for the period | 70,175 | 65,682 | 72,740 |
| Equity attributable to owner of the Parent company | 79,293 | 81,717 | 88,314 |
| Non-controlling interests | 411 | 459 | 427 |
| Total equity | 79,704 | 82,176 | 88,741 |
| Non-current liabilities | |||
| Non-current financial liabilities | 38,161 | 40,332 | 40,674 |
| Provisions for pensions | 1,571 | 2,537 | 2,578 |
| Deferred tax liabilities | 6,699 | 7,108 | 6,978 |
| Other non-current provisions | 400 | 433 | 507 |
| Other non-current liabilities | 516 | 1,051 | 516 |
| Total non-current liabilities | 47,347 | 51,461 | 51,253 |
| Current liabilities | |||
| Current financial liabilities | 2,516 | 11,905 | 6,424 |
| Trade payables | 15,675 | 16,171 | 17,098 |
| Current tax liabilities | 1,364 | 2,475 | 1,442 |
| Current provisions | 1,211 | 1,453 | 1,377 |
| Other current liabilities | 23,424* | 20,435 | 18,949 |
| Total current liabilities | 44,190 | 52,439 | 45,290 |
| Total equity and liabilities | 171,241 | 186,076 | 185,284 |
*) Of this amount, SEK 5,711m represents a liability relating to the dividend for Essity's shareholders paid on April 3, 2025 as decided at the Annual General Meeting on March 27, 2025.
| SEKm | Mar 31, 2025 | Mar 31, 2024 | Dec 31, 2024 |
|---|---|---|---|
| Equity attributable to owners of the Parent company | |||
| Value, beginning of the period | 88,314 | 70,846 | 70,846 |
| Total comprehensive income for the period | -2,527 | 16,330 | 24,719 |
| Dividend | -5,711* | -5,443 | -5,443 |
| Repurchase of own shares | -776 | ─ | -2,224 |
| Acquisition of non-controlling interests | ─ | ─ | -8 |
| Transferred to cost of hedged investments | 5 | 5 | 31 |
| Revaluation effect upon acquisition of non-controlling interests |
-12 | -21 | 393 |
| Value, end of period | 79,293 | 81,717 | 88,314 |
| Non-controlling interests | |||
| Value, beginning of period | 427 | 8,559 | 8,559 |
| Total comprehensive income for the period | -16 | 525 | 558 |
| Dividend | ─ | -1 | -23 |
| Divestment of non-controlling interests | ─ | -8,624 | -8,624 |
| Acquisition of non-controlling interests | ─ | ─ | -43 |
| Value, end of period | 411 | 459 | 427 |
| Total equity, value end of period | 79,704 | 82,176 | 88,741 |
*) Dividend of SEK 5,711m resolved by the Annual General Meeting on March 27, 2025. Payment on April 3, 2025.
| SEKm | 2503 | 2403 |
|---|---|---|
| Operating activities | ||
| Operating profit | 4,482 | 4,134 |
| Adjustments for non-cash items1) | 1,875 | 2,154 |
| Operating profit excluding non-cash items | 6,357 | 6,288 |
| Interest paid | -1,011 | -951 |
| Interest received | 117 | 113 |
| Other financial items | -32 | 181 |
| Capitalized expenditures to fulfill contracts with customers | -118 | -105 |
| Change in liabilities relating to restructuring programs, etc. | -143 | -189 |
| Paid tax | -1,222 | -1,013 |
| Cash flow from operating activities before changes in working capital | 3,948 | 4,324 |
| Cash flow from changes in working capital | ||
| Change in inventories | -868 | -557 |
| Change in operating receivables | 301 | -306 |
| Change in operating liabilities | -465 | 572 |
| Cash flow from operating activities, continuing operations | 2,916 | 4,033 |
| Cash flow from operating activities, discontinued operations | ─ | -368 |
| Cash flow from operating activities, total operations | 2,916 | 3,665 |
| Investing activities | ||
| Acquisitions of Group companies and other operations | ─ | -17 |
| Divestments of Group companies and other operations | ─ | 17,980 |
| Investments in intangible assets and property, plant and equipment | -1,144 | -1,399 |
| Paid interest capitalized in intangible assets and property, plant and equipment | -6 | -11 |
| Sale of property, plant and equipment | 17 | 1 |
| Purchase and sale of financial assets with short maturities | 2,863 | -452 |
| Cash flow from investing activities, continuing operations | 1,730 | 16,102 |
| Cash flow from investing activities, discontinued operations | ─ | -87 |
| Cash flow from investing activities, total operations | 1,730 | 16,015 |
| SEKm | 2503 | 2403 |
|---|---|---|
| Financing activities | ||
| Proceeds from borrowings2) | 42 | 34 |
| Repayment of borrowings2) | -4,227 | -6,950 |
| Payment of lease liabilities2) | -289 | -263 |
| Change in borrowings with short maturities, etc.2) | -413 | -2,814 |
| Dividend | ─3) | -5,443 |
| Dividend to non-controlling interests | ─ | -1 |
| Repurchase of own shares | -776 | ─ |
| Cash flow from financing activities, continuing operations | -5,663 | -15,437 |
| Cash flow from financing activities, discontinued operations | ─ | -12 |
| Cash flow from financing activities, total operations | -5,663 | -15,449 |
| Cash flow for the period, continuing operations | -1,017 | 4,698 |
| Cash flow for the period, discontinued operations | ─ | -467 |
| Cash flow for the period, total operations | -1,017 | 4,231 |
| Cash and cash equivalents at the beginning of the period | 10,962 | 6,927 |
| Translation differences in cash and cash equivalents | -178 | 215 |
| Cash and cash equivalents at the end of the period, total operations | 9,767 | 11,373 |
| SEKm | 2503 | 2403 |
|---|---|---|
| Depreciation/amortization and impairment of non-current assets | 1,747 | 2,079 |
| Depreciation of capitalized selling expenses | 120 | 115 |
| Gain/loss on sale of assets | ─ | 8 |
| Non-cash items relating to restructuring programs | 2 | 61 |
| Other | 6 | -109 |
| Total | 1,875 | 2,154 |
2) From the second quarter of 2024, changes in borrowings with short maturities, etc. are presented separately in the cash flow statement. From the fourth quarter of 2024, payments of lease liabilities are presented separately in the cash flow statement. The comparative figures have been restated.
3) Dividend of SEK 5,711m resolved by the Annual General Meeting on March 27, 2025. Payment on April 3, 2025.
| SEKm | 2503 | 2403 |
|---|---|---|
| Reconciliation with consolidated operating cash flow statement | ||
| Cash flow for the period, continuing operations | -1,017 | 4,698 |
| Proceeds from borrowings1) | -42 | -34 |
| Repayment of borrowings1) | 4,227 | 6,950 |
| Payment of lease liabilities1) | 289 | 263 |
| Change in borrowings with short maturities, etc.1) | 413 | 2,814 |
| Purchase and sale of financial assets with short maturities | -2,863 | 452 |
| Net debt in acquired and divested operations | ─ | 5,928 |
| Investments in operating assets through leases | -166 | -40 |
| Accrued interest, etc. | 553 | 50 |
| Net cash flow according to consolidated operating cash flow statement | 1,394 | 21,081 |
1) From the second quarter of 2024, changes in borrowings with short maturities, etc. are presented separately in the cash flow statement. From the fourth quarter of 2024, payments of lease liabilities are presented separately in the cash flow statement. The comparative figures have been restated.
| SEKm | 2503 | 2403 |
|---|---|---|
| Administrative expenses | -199 | -426 |
| Other operating income | -7 | 12 |
| Operating loss | -206 | -414 |
| Financial items | -672 | 11,278 |
| Profit/loss before tax | -878 | 10,864 |
| Income taxes | 16 | 91 |
| Profit/loss for the period | -862 | 10,955 |
| SEKm | 2503 | 2403 |
|---|---|---|
| Profit/loss for the period | -862 | 10,955 |
| Other comprehensive income for the period | ─ | ─ |
| Total comprehensive income for the period | -862 | 10,955 |
| SEKm | Mar 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Assets | ||
| Intangible assets | 0 | 0 |
| Property, plant and equipment | 11 | 12 |
| Financial non-current assets | 177,095 | 177,152 |
| Total non-current assets | 177,106 | 177,164 |
| Total current assets | 579 | 770 |
| Total assets | 177,685 | 177,934 |
| Equity, provisions and liabilities | ||
| Equity | ||
| Restricted equity | 2,350 | 2,350 |
| Non-restricted equity | 74,664* | 82,013 |
| Total equity | 77,014 | 84,363 |
| Untaxed reserves | 827 | 827 |
| Provisions | 779 | 818 |
| Non-current liabilities | 35,824 | 37,877 |
| Current liabilities | 63,241* | 54,049 |
| Total equity, provisions and liabilities | 177,685 | 177,934 |
*) The Annual General Meeting on March 27, 2025 resolved to distribute SEK 5,711m to Essity's shareholders, which is recognized as a current liability at March 31, 2025.
This interim report has been prepared in accordance with IAS 34 and recommendation RFR 1 of the Swedish Corporate Reporting Board and RFR 2 for the Parent company. On January 1, 2025, the International Accounting Standards Board (IASB®) published amendments to IAS 21, The Effects of Changes in Foreign Exchange Rates: nonexchangeability, that entered into force following approval by the EU. Essity Aktiebolag (publ) applies this amendment, which has not had any material impact on the Group's or the Parent company's financial statements.
In other respects, the accounting principles and calculation methods applied correspond to those described in Essity's 2024 Annual Report.
Essity's Board determines the Group's strategic direction based on recommendations from the Executive Management Team. Responsibility for the long-term, overall management of strategic risks corresponds to the company's delegation structure, from the Board of Directors to the CEO and from the CEO to the Business Unit Presidents. This means that most operational risks are managed by Essity's business units at the local level, but they are centrally coordinated when considered necessary. The tools used for coordination consist primarily of the business units' regular reporting and the annual strategy process, which includes risks and risk management.
Essity's financial risk management is centralized, as is its internal bank for financial transactions conducted by Group companies and the management of the Group's energy risks. Financial risks are managed in accordance with the Group's Finance Policy, which is adopted by Essity's Board and, together with Essity's Energy Risk Policy, provides a management framework. Risks are continuously compiled and monitored to ensure compliance with these guidelines. Essity has also centralized other risk management.
Essity has a staff function for internal audit, which monitors compliance with the Group's policies.
Essity's risk exposure and risk management are described on pages 41–46 in the 2024 Annual Report and in the sections under environmental information and social information on pages 59–61. No significant changes have taken place that have affected the reported risks.
Risks in conjunction with company acquisitions are analyzed in the due diligence processes that Essity carries out prior to all acquisitions. In cases where acquisitions have been carried out that may affect the assessment of Essity's risk exposure, these are described under the heading "Events during the quarter" in the interim or year-end reports.
The introduction or escalation of trade disputes, such as the imposition of significantly higher tariffs by the US administration on imports from certain trading partners, and any subsequent retaliation by such trading partners, may have an impact on tariffs or other barriers imposed on importers of goods between territories. This could directly or indirectly affect the Group's financial position and operating results, by increasing the prices of its products, weakening consumer purchasing power or otherwise causing economic instability in the affected countries.
Measurement principles and classifications of financial instruments, as described in Essity's 2024 Annual Report, Note E1, were applied consistently throughout the reporting period. Financial liabilities are measured at amortized cost provided they are not part of a fair value hedge when they are recognized at fair value through profit or loss. The fair value of trade receivables, other current and non-current receivables, cash and cash equivalents, trade payables and other current and non-current liabilities is estimated to be equal to their carrying amount.
| Carrying | Carrying amount in |
||||
|---|---|---|---|---|---|
| amount in the | the balance | Measurement | |||
| SEKm | balance sheet | Fair value | sheet | Fair value | level 1) |
| Mar 31, 2025 | Mar 31, 2025 | Dec 31, 2024 | Dec 31, 2024 | ||
| Assets | |||||
| Derivatives | 1,523 | 1,523 | 1,102 | 1,102 | 2 |
| Non-current financial assets | 102 | 102 | 109 | 109 | 1 |
| Total assets | 1,625 | 1,625 | 1,211 | 1,211 | |
| Liabilities | |||||
| Derivatives | 3,324 | 3,324 | 3,304 | 3,304 | 2 |
| Current financial liabilities 2) | 184 | 184 | 4,572 | 4,572 | 2 |
| Non-current financial liabilities 2) |
33,077 | 32,321 | 34,962 | 34,176 | 2 |
1) No financial instruments have been classified to level 3.
2) The measurement level refers to liabilities measured at fair value in a hedging relationship.
| 2025:1 | 2024:1 | |
|---|---|---|
| Number of shares, end of period | 702,342,489 | 702,342,489 |
| Of which class A-shares | 58,973,654 | 60,970,043 |
| Of which class B-shares | 643,368,835 | 641,372,446 |
| Number of Class B shares held by Essity, end of period |
10,070,500 | 0 |
| Number of outstanding shares before and after dilution, end of period |
692,271,989 | 702,342,489 |
| Average number of Class B shares held by Essity, end of period |
8,981,594 | 0 |
| Average number of shares before and after dilution |
693,360,895 | 702,342,489 |
At the Annual General Meeting on March 27, 2025, a resolution was passed to cancel the company's own shares, which was carried out after the end of the quarter. Following the cancellation of 9,288,000 Class B shares, Essity now has a total of 693,054,489 outstanding shares.
On March 21, 2024, Essity completed the divestment of its holding of 51.59% of shares in the Asian hygiene company Vinda International Holdings Limited (Vinda). The sales proceeds amounted to approximately HKD 14.6bn (SEK 19,360m).
| SEKm | 2503 | 2403 |
|---|---|---|
| Profit for the period, Vinda | ─ | 217 |
| Other profit for the period, Vinda | ─ | 8,7991) |
| Profit for the period, discontinued operations | ─ | 9,016 |
| 1) Of which: | ||
| Profit from divestment | ─ | 8,366 |
| Reclassification of realized translation differences after tax | ─ | 748 |
| Transaction cost | ─ | -226 |
| Impairment of Essity owned intangible asset related to Vinda after tax | ─ | -89 |
| SEKm | 2503 | 2403 |
|---|---|---|
| Net sales | ─ | 4,533 |
| Operating expenses | ─ | -4,261 |
| Operating profit | ─ | 272 |
| Financial items | ─ | -27 |
| Profit before tax | ─ | 245 |
| Income taxes | ─ | -28 |
| Profit for the period, discontinued operations | ─ | 217 |
| SEKm | 2503 | 2403 |
|---|---|---|
| Profit for the period, discontinued operations attributable to: | ||
| Owners of the Parent company | ─ | 8,920 |
| Non-controlling interests | ─ | 96 |
| Earnings per share, discontinued operations - Owners of the parent company | ||
| Earnings per share, discontinued operations before and after dilution effects, SEK |
─ | 12.70 |
| Average numbers of shares before and after dilution, million | ─ | 702.3 |
Guidelines for Alternative Performance Measures (APMs) for companies with securities listed on a regulated market in the EU have been issued by ESMA (European Securities and Markets Authority). These guidelines are to be applied for APMs not supported under IFRS.
This interim report refers to a number of performance measures not defined in IFRS. These performance measures are used to help investors, management and other stakeholders to analyze the company's operations. These non-IFRS performance measures may differ from similarly titled measures among other companies. Essity's Annual Report 2024, pages 124–128, describes the various non-IFRS performance measures that are used as a complement to the financial information presented in accordance with IFRS. Abbreviations are used in the report for the performance and return measures below.
| Abbreviation | Complete expression |
|---|---|
| EBITA | Operating profit before amortization of acquisition-related intangible assets |
| EBITDA | Operating profit before depreciation and amortization of property, plant and equipment and intangible assets |
| IAC | Items affecting comparability |
| ROCE | Return on capital employed |
| ROE | Return on equity |
| SEKm | 2503 | 2403 | 2412 |
|---|---|---|---|
| Total assets | 171,241 | 186,076 | 185,284 |
| -Financial assets | -15,474 | -20,511 | -18,907 |
| -Non-current non-interest bearing liabilities | -7,615 | -8,592 | -8,001 |
| -Current non-interest bearing liabilities | -41,674* | -40,534 | -38,866 |
| Capital employed | 106,478 | 116,439 | 119,510 |
*) Of this amount, SEK 5,711m represents a liability relating to the dividend for Essity's shareholders paid on April 3, 2025 as decided at the Annual General Meeting on March 27, 2025.
| SEKm | 2503 | 2403 | 2412 |
|---|---|---|---|
| Inventories | 18,493 | 19,031 | 18,914 |
| Trade receivables | 22,278 | 23,686 | 23,538 |
| Other current receivables | 3,586 | 3,267 | 4,480 |
| Trade payables | -15,675 | -16,171 | -17,098 |
| Other current liabilities | -23,424* | -20,435 | -18,949 |
| Other | -47 | 231 | -139 |
| Working capital | 5,211 | 9,609 | 10,746 |
*) Of this amount, SEK 5,711m represents a liability relating to the dividend for Essity's shareholders paid on April 3, 2025 as decided at the Annual General Meeting on March 27, 2025.
| SEKm | 2503 | 2403 | 2412 |
|---|---|---|---|
| Surplus in funded pension plans | 2,593 | 4,012 | 2,475 |
| Non-current financial assets | 221 | 123 | 128 |
| Current financial assets | 2,893 | 5,003 | 5,342 |
| Cash and cash equivalents | 9,767 | 11,373 | 10,962 |
| Financial assets | 15,474 | 20,511 | 18,907 |
| Non-current financial liabilities | 38,161 | 40,332 | 40,674 |
| Provisions for pensions | 1,571 | 2,537 | 2,578 |
| Current financial liabilities | 2,516 | 11,905 | 6,424 |
| Financial liabilities | 42,248 | 54,774 | 49,676 |
| Net debt, total operations | 26,774 | 34,263 | 30,769 |
| SEKm | 2025:1 | 2024:1 |
|---|---|---|
| Operating profit | 4,482 | 4,134 |
| -Amortization of acquisition-related intangible assets | 256 | 320 |
| -Items affecting comparability (IAC) - impairment of acquisition related intangible assets | -20 | 69 |
| Operating profit before amortization and impairment of acquisition-related intangible assets (EBITA) |
4,718 | 4,523 |
| EBITA margin (%) | 13.5 | 13.0 |
| -Items affecting comparability (IAC) - cost of goods sold | 10 | 366 |
| -Items affecting comparability (IAC) - sales, general and administration | -22 | -9 |
| EBITA excl. IAC | 4,706 | 4,880 |
| EBITA margin excl. IAC (%) | 13.5 | 14.0 |
| SEKm | 2025:1 | 2024:1 |
|---|---|---|
| Operating profit | 4,482 | 4,134 |
| -Amortization of acquisition-related intangible assets | 256 | 320 |
| -Depreciation/amortization | 1,227 | 1,219 |
| -Depreciation right-of-use asset | 282 | 267 |
| -Impairment | 3 | ─ |
| -Items affecting comparability (IAC) - impairment net | -1 | 204 |
| -Items affecting comparability (IAC) - impairment of acquisition-related intangible assets | -20 | 69 |
| EBITDA | 6,229 | 6,213 |
| -Items affecting comparability (IAC) excluding depreciation/amortization and impairment | -11 | 153 |
| EBITDA excl. IAC | 6,218 | 6,366 |
1)
| SEKm | 2025:1 | 2024:1 |
|---|---|---|
| Organic sales growth | 743 | -1,461 |
| Acquisitions | ─ | ─ |
| Divestments | -10 | -693 |
| Exchange rate effect1) | -607 | 651 |
| Recognized change | 126 | -1,503 |
Consists solely of currency translation effects
The tables below show parts of the income statement broken down by operating segment: Health & Medical, Consumer Goods and Professional Hygiene.
| SEKm | 2025:1 | ||||
|---|---|---|---|---|---|
| Health & | Consumer | Professional | Other | Total | |
| Medical | Goods | Hygiene | operations | Group | |
| Net sales | 6,936 | 19,285 | 8,757 | -2 | 34,976 |
| Cost of goods sold | -3,856 | -13,589 | -6,039 | -18 | -23,502 |
| Sales, general and administration | -1,849 | -3,253 | -1,305 | -361 | -6,768 |
| Share of results of associates and joint ventures |
─ | ─ | ─ | ─ | ─ |
| Operating profit/loss before amortization of acquisition-related intangible assets (EBITA) excl. IAC |
1,231 | 2,443 | 1,413 | -381 | 4,706 |
| Amortization of acquisition-related intangible assets |
-193 | -58 | -5 | 0 | -256 |
| Operating profit/loss excl. IAC | 1,038 | 2,385 | 1,408 | -381 | 4,450 |
| Items affecting comparability (IAC) | 30 | 12 | -10 | 0 | 32 |
| Operating profit/loss | 1,068 | 2,397 | 1,398 | -381 | 4,482 |
| Share of results of associates and joint ventures |
-1 | ||||
| Financial items | -373 | ||||
| Tax expense for the period | -1,025 | ||||
| Profit for the period, continuing operations |
3,083 |
| SEKm | 2024:1 | ||||
|---|---|---|---|---|---|
| Health & | Consumer | Professional | Other | Total | |
| Medical | Goods | Hygiene | operations | Group | |
| Net sales | 6,842 | 19,338 | 8,686 | -16 | 34,850 |
| Cost of goods sold | -3,746 | -13,465 | -6,090 | 18 | -23,283 |
| Sales, general and administration | -1,806 | -3,329 | -1,265 | -289 | -6,689 |
| Share of results of associates and joint ventures |
─ | 1 | 1 | ─ | 2 |
| Operating profit/loss before amortization of acquisition-related intangible assets (EBITA) excl. IAC |
1,290 | 2,545 | 1,332 | -287 | 4,880 |
| Amortization of acquisition-related intangible assets |
-255 | -60 | -5 | ─ | -320 |
| Operating profit/loss excl. IAC | 1,035 | 2,485 | 1,327 | -287 | 4,560 |
| Items affecting comparability (IAC) | -46 | -265 | -116 | 1 | -426 |
| Operating profit/loss | 989 | 2,220 | 1,211 | -286 | 4,134 |
| Share of results of associates and joint ventures |
─ | ||||
| Financial items | -607 | ||||
| Tax expense for the period | -1,050 | ||||
| Profit for the period, continuing operations | 2,477 |
| 2025:1 | 2024:4 | 2024:3 | 2024:2 | 2024:1 | 2023:4 | 2023:3 | 2023:2 | 2023:1 | Margins (%) | 2025:1 | 2024:4 | 2024:3 | 2024:2 | 2024:1 | 2023:4 | 2023:3 | 2023:2 | 2023:1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales, SEKm | 34,976 | 37,805 | 36,274 | 36,617 | 34,850 | 36,625 | 37,092 | 37,078 | 36,352 | Gross margin | 32.8 | 31.7 | 33.0 | 32.8 | 32.1 | 31.9 | 28.8 | 28.2 | 28.5 |
| Organic sales | 2.1 | 3.9 | 1.9 | -0.9 | -4.0 | -0.7 | 2.4 | 7.7 | 15.9 | Gross margin excl. IAC |
32.8 | 31.9 | 32.6 | 33.2 | 33.2 | 32.0 | 31.5 | 29.2 | 28.4 |
| growth, % | EBITA margin | 13.5 | 12.1 | 14.1 | 14.3 | 13.0 | 12.6 | 9.4 | 11.1 | 12.0 | |||||||||
| Gross profit, SEKm | 11,464 | 11,968 | 11,962 | 12,003 | 11,201 | 11,675 | 10,683 | 10,454 | 10,359 | EBITA margin | |||||||||
| Gross profit excl. IAC, SEKm |
11,474 | 12,074 | 11,826 | 12,150 | 11,567 | 11,720 | 11,670 | 10,809 | 10,321 | excl. IAC Operating |
13.5 12.8 |
13.1 11.4 |
14.1 13.4 |
14.7 13.6 |
14.0 11.9 |
13.3 11.9 |
13.9 7.8 |
12.5 10.3 |
11.8 11.2 |
| EBITA, SEKm | 4,718 | 4,585 | 5,130 | 5,237 | 4,523 | 4,611 | 3,497 | 4,131 | 4,368 | margin Operating |
|||||||||
| EBITA excl. IAC, | margin excl. | 12.7 | 12.4 | 13.3 | 14.0 | 13.1 | 12.5 | 13.1 | 11.7 | 11.0 | |||||||||
| SEKm Operating profit, |
4,706 | 4,969 | 5,097 | 5,398 | 4,880 | 4,853 | 5,147 | 4,617 | 4,281 | IAC Financial net margin |
-1.1 | -1.1 | -1.2 | -1.3 | -1.7 | -1.4 | -1.7 | -1.6 | -1.7 |
| SEKm | 4,482 | 4,315 | 4,868 | 4,978 | 4,134 | 4,341 | 2,903 | 3,819 | 4,085 | Profit margin | 11.7 | 10.3 | 12.2 | 12.3 | 10.2 | 10.5 | 6.1 | 8.7 | 9.5 |
| Profit for the period, SEKm |
3,083 | 2,893 | 3,329 | 3,334 | 2,477 | 2,858 | 1,563 | 2,445 | 2,651 | Profit margin excl. IAC |
11.6 | 11.3 | 12.1 | 12.7 | 11.4 | 11.1 | 11.4 | 10.1 | 9.3 |
| Operating cash flow, SEKm |
3,765 | 3,297 | 6,453 | 3,239 | 4,253 | 5,914 | 6,054 | 2,847 | 2,870 | Income taxes | -2.9 | -2.7 | -3.1 | -3.2 | -3.0 | -2.7 | -1.9 | -2.1 | -2.2 |
| ROCE, % | 16.7 | 15.8 | 17.8 | 17.9 | 15.9 | 16.2 | 11.7 | 14.2 | 15.5 | Income taxes excl. IAC |
-2.9 | -2.8 | -3.0 | -3.3 | -3.3 | -2.9 | -2.7 | -2.5 | -2.2 |
| ROCE excl. IAC, % | 16.7 | 17.1 | 17.7 | 18.5 | 17.2 | 17.1 | 17.2 | 15.8 | 15.2 | Net margin | 8.8 | 7.6 | 9.1 | 9.1 | 7.2 | 7.8 | 4.2 | 6.6 | 7.3 |
| Capital employed, SEKm |
106,478 | 119,510 | 112,957 | 117,076 | 116,439 | 110,750 | 116,928 | 122,817 | 110,265 | Net margin excl. IAC |
8.7 | 8.5 | 9.1 | 9.4 | 8.1 | 8.2 | 8.7 | 7.6 | 7.1 |
| ROE, % | 14.6 | 13.4 | 15.9 | 16.1 | 56.9 | 14.4 | 8.2 | 13.3 | 14.4 | ||||||||||
| ROE excl. IAC, % | 14.5 | 14.9 | 15.8 | 16.6 | 15.0 | 15.5 | 16.5 | 15.2 | 14.0 | ||||||||||
| Debt/equity ratio, % | 0.34 | 0.35 | 0.35 | 0.40 | 0.42 | 0.68 | 0.75 | 0.86 | 0.84 | ||||||||||
| Equity/assets ratio, % |
46 | 48 | 46 | 46 | 44 | 35 | 34 | 32 | 30 | ||||||||||
| Net debt, SEKm | 26,774 | 30,769 | 29,122 | 33,214 | 34,263 | 53,703 | 60,633 | 69,124 | 62,114 | ||||||||||
| Earnings per share, SEK |
4.43 | 4.13 | 4.73 | 4.72 | 3.51 | 4.04 | 2.20 | 3.46 | 3.75 | ||||||||||
| Earnings per share excl. IAC, SEK |
4.65 | 4.85 | 4.97 | 5.13 | 4.33 | 4.54 | 4.83 | 4.26 | 3.93 | ||||||||||
| Equity per share, SEK | 115 | 127 | 119 | 119 | 117 | 113 | 115 | 114 | 105 |
| Net sales | Capital employed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SEKm | 2025:1 | 2024:4 | 2024:3 | 2024:2 | 2024:1 | 2023:4 | 2023:3 | 2023:2 | 2023:1 | SEKm | 2025:1 | 2024:4 | 2024:3 | 2024:2 | 2024:1 | 2023:4 | 2023:3 | 2023:2 | 2023:1 |
| Health & Medical | 6,936 | 7,417 | 7,127 | 7,213 | 6,842 | 7,001 | 7,158 | 6,905 | 6,665 | Health & Medical | 32,366 | 34,566 | 33,112 | 34,245 | 34,153 | 32,762 | 34,956 | 36,532 | 34,472 |
| Consumer Goods | 19,285 | 20,472 | 19,410 | 19,672 | 19,338 | 19,870 | 19,729 | 20,056 | 20,257 | Consumer Goods | 52,093 | 55,293 | 52,560 | 54,342 | 54,612 | 52,009 | 54,676 | 56,725 | 52,926 |
| Professional Hygiene | 8,757 | 9,923 | 9,729 | 9,729 | 8,686 | 9,752 | 10,184 | 10,123 | 9,422 | Professional Hygiene | 25,494 | 25,998 | 24,501 | 25,976 | 25,663 | 24,021 | 25,765 | 28,225 | 27,500 |
| Other | -2 | -7 | 8 | 3 | -16 | 2 | 21 | -6 | 8 | Other | -3,475* | 3,653 | 2,784 | 2,513 | 2,011 | 1,958 | 1,531 | 1,335 | -4,633** |
| Total | 34,976 | 37,805 | 36,274 | 36,617 | 34,850 | 36,625 | 37,092 | 37,078 | 36,352 | Total | 106,478 | 119,510 | 112,957 | 117,076 | 116,439 | 110,750 | 116,928 | 122,817 | 110,265 |
| Organic sales growth % |
2025:1 | 2024:4 | 2024:3 | 2024:2 | 2024:1 | 2023:4 | 2023:3 | 2023:2 | 2023:1 | ) Of this amount, SEK 5,711m represents a liability relating to the dividend for Essity's shareholders paid on April 3, 2025 as decided at the Annual General Meeting on March 27, 2025. *) Of this amount, SEK 5,092m represents a liability relating to the dividend for Essity's shareholders paid on April 5, 2023 as decided at the Annual General Meeting on March 29, 2023. |
|||||||||
ROCE excl. IAC
Operating cash flow
| Health & Medical | 1.7 | 5.6 | 2.8 | 4.5 | 2.6 | 4.3 | 5.8 | 8.0 | 10.6 |
|---|---|---|---|---|---|---|---|---|---|
| Consumer Goods | 2.9 | 4.5 | 3.0 | -1.3 | -4.8 | -2.8 | -0.4 | 5.7 | 14.8 |
| Professional Hygiene | 0.7 | 1.4 | -0.8 | -3.9 | -6.9 | 0.1 | 5.7 | 11.7 | 22.6 |
| Total | 2.1 | 3.9 | 1.9 | -0.9 | -4.0 | -0.7 | 2.4 | 7.7 | 15.9 |
| % | 2025:1 | 2024:4 | 2024:3 | 2024:2 | 2024:1 | 2023:4 | 2023:3 | 2023:2 | 2023:1 |
|---|---|---|---|---|---|---|---|---|---|
| Health & Medical | 14.7 | 16.1 | 16.5 | 17.2 | 15.4 | 13.3 | 13.3 | 10.7 | 9.1 |
| Consumer Goods | 18.2 | 16.7 | 17.1 | 17.9 | 19.1 | 19.4 | 17.2 | 17.6 | 18.2 |
| Professional Hygiene | 22.0 | 28.8 | 28.7 | 28.9 | 21.4 | 24.6 | 28.0 | 22.7 | 18.6 |
| Total | 16.7 | 17.1 | 17.7 | 18.5 | 17.2 | 17.1 | 17.2 | 15.8 | 15.2 |
| SEKm | 2025:1 | 2024:4 | 2024:3 | 2024:2 | 2024:1 | 2023:4 | 2023:3 | 2023:2 | 2023:1 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Health & Medical | 1,231 | 1,361 | 1,386 | 1,472 | 1,290 | 1,125 | 1,188 | 947 | 777 | |
| Consumer Goods | 2,443 | 2,245 | 2,285 | 2,434 | 2,545 | 2,585 | 2,395 | 2,417 | 2,400 | |
| Professional Hygiene | 1,413 | 1,817 | 1,812 | 1,868 | 1,332 | 1,531 | 1,887 | 1,582 | 1,288 | |
| Other | -381 | -454 | -386 | -376 | -287 | -388 | -323 | -329 | -184 | |
| Total | 4,706 | 4,969 | 5,097 | 5,398 | 4,880 | 4,853 | 5,147 | 4,617 | 4,281 | |
| EBITA margin excl. IAC | ||||||||||
| % | 2025:1 | 2024:4 | 2024:3 | 2024:2 | 2024:1 | 2023:4 | 2023:3 | 2023:2 | 2023:1 |
|---|---|---|---|---|---|---|---|---|---|
| Health & Medical | 17.7 | 18.3 | 19.4 | 20.4 | 18.9 | 16.1 | 16.6 | 13.7 | 11.7 |
| Consumer Goods | 12.7 | 11.0 | 11.8 | 12.4 | 13.2 | 13.0 | 12.1 | 12.1 | 11.8 |
| Professional Hygiene | 16.1 | 18.3 | 18.6 | 19.2 | 15.3 | 15.7 | 18.5 | 15.6 | 13.7 |
| Total | 13.5 | 13.1 | 14.1 | 14.7 | 14.0 | 13.3 | 13.9 | 12.5 | 11.8 |
| SEKm | 2025:1 | 2024:4 | 2024:3 | 2024:2 | 2024:1 | 2023:4 | 2023:3 | 2023:2 | 2023:1 |
|---|---|---|---|---|---|---|---|---|---|
| Health & Medical | 1,232 | 976 | 1,674 | 879 | 1,330 | 1,411 | 1,676 | 323 | 270 |
| Consumer Goods | 1,657 | 1,114 | 2,793 | 1,442 | 2,331 | 2,506 | 2,235 | 1,732 | 1,760 |
| Professional Hygiene | 1,054 | 1,678 | 2,153 | 1,538 | 780 | 2,227 | 2,370 | 1,782 | 951 |
| Other | -178 | -471 | -167 | -620 | -188 | -230 | -227 | -990 | -111 |
| Total | 3,765 | 3,297 | 6,453 | 3,239 | 4,253 | 5,914 | 6,054 | 2,847 | 2,870 |
President and CEO Magnus Groth and Executive Vice President and CFO Fredrik Rystedt will present the interim report at a live webcast and teleconference at 09:00 CET on April 24, 2025.
Link to the live presentation, which can also be viewed afterwards: https://essity.videosync.fi/2025-04-24-q1
Contact information for conference call with the possibility to ask questions:
UK: +44 (0) 33 0551 02 00 USA: +1 786 697 35 01 SWE: +46 (0) 8 505 204 24
Please call in well in advance of the start of the presentation. Indicate: "Essity".
Fredrik Rystedt, Executive Vice President and CFO, tel: +46 (0) 8 788 51 31 Sandra Åberg, Vice President Investor Relations, tel: +46 (0) 70 564 96 89 Per Lorentz, Vice President Corporate Communications, tel: +46 (0) 73 313 30 55 Essity is a global, leading hygiene and health company. Every day, our products, solutions and services are used by a billion people around the world. Our purpose is to break barriers to well-being for the benefit of consumers, patients, caregivers, customers and society. Sales are conducted in approximately 150 countries under the leading global brands TENA and Tork, and other strong brands such as Actimove, Cutimed, JOBST, Knix, Leukoplast, Libero, Libresse, Lotus, Modibodi, Nosotras, Saba, Tempo, TOM Organic and Zewa. In 2024, Essity had net sales of approximately SEK 146bn (EUR 13bn) and employed 36,000 people. The company's headquarter is in Stockholm, Sweden and Essity is listed on Nasdaq Stockholm.
More information at essity.com and follow Essity on social media.

Every day we improve hygiene and health for a billion people in 150 countries
Interim report, Quarter 2, 2025 July 17, 2025 Interim report, Quarter 3, 2025 October 23, 2025 Interim report, Quarter 4 and full-year, 2025 January 22, 2026 Annual Report 2025 March 2026
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.